LYS THERAPEUTICS

French tech company | Builders Republic

About

Clinical-stage neurology biotech developing LYS241, a first-in-class candidate targeting neurovascular / neurological disorders — spun out of academic research and advancing toward clinical milestones.

Key facts

Status
Active
Sectors
Healthcare & Life Sciences
Latest stage
Series A
Founded
2021
City
CAEN
Region
Normandie
Tracked rounds
2
Amount raised
≥ 3.0 M€ raised since 2020

Funding rounds

  • Series A — 2026
  • Seed — 2022

Investors